Nucmito Pharmaceuticals Co., Ltd.

China

Back to Profile

1-8 of 8 for Nucmito Pharmaceuticals Co., Ltd. Sort by
Query
Aggregations
Jurisdiction
        World 5
        Canada 2
        United States 1
Date
2025 (YTD) 1
2024 1
2023 1
2022 2
2021 1
IPC Class
A61K 31/015 - Hydrocarbons carbocyclic 6
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics 6
C07C 13/465 - IndenesCompletely or partially hydrogenated indenes 6
A61P 35/00 - Antineoplastic agents 5
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans 1
See more
Status
Pending 3
Registered / In Force 5
Found results for  patents

1.

RXR-ALPHA MODULATORS FOR TREATING MALIGNANCY

      
Application Number CN2024117106
Publication Number 2025/051192
Status In Force
Filing Date 2024-09-05
Publication Date 2025-03-13
Owner NUCMITO PHARMACEUTICALS COMPANY LIMITED (China)
Inventor
  • Zhang, Xiaokun
  • Zhou, Yuqi
  • Su, Ying
  • Wang, Haishan

Abstract

Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a malignancy with an RXRα modulator.

IPC Classes  ?

  • A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
  • A61K 31/015 - Hydrocarbons carbocyclic
  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes
  • A61P 35/00 - Antineoplastic agents

2.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Application Number CN2023131809
Publication Number 2024/104384
Status In Force
Filing Date 2023-11-15
Publication Date 2024-05-23
Owner NUCMITO PHARMACEUTICALS CO. LTD. (China)
Inventor
  • Chen, Ziwen
  • Su, Ying
  • Wang, Haishan

Abstract

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

IPC Classes  ?

  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 35/00 - Antineoplastic agents

3.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Application Number 18001309
Status Pending
Filing Date 2021-06-11
First Publication Date 2023-07-27
Owner NUCMITO PHARMACEUTICALS CO. LTD. (China)
Inventor
  • Su, Ying
  • Zhang, Xiaokun
  • Chen, Ziwen
  • Chen, Qingzhen
  • Wang, Haishan
  • Zhang, Xindao
  • Zeng, Zhiping
  • Cai, Lijun
  • Zhou, Yuqi

Abstract

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease. Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

IPC Classes  ?

  • C07C 59/135 - Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing halogen
  • C07D 215/20 - Oxygen atoms
  • C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C 229/44 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
  • C07D 257/06 - Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
  • C07D 257/04 - Five-membered rings
  • C07D 233/88 - Nitrogen atoms, e.g. allantoin
  • C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
  • C07D 207/327 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
  • C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
  • C07D 213/643 - 2-PhenoxypyridinesDerivatives thereof
  • C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
  • C07C 255/57 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07D 271/07 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

4.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Application Number CN2022092918
Publication Number 2022/242582
Status In Force
Filing Date 2022-05-16
Publication Date 2022-11-24
Owner NUCMITO PHARMACEUTICALS COMPANY LIMITED (China)
Inventor
  • Su, Ying
  • Chen, Ziwen
  • Wang, Haishan
  • Zhou, Yuqi
  • Zhang, Xindao

Abstract

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

IPC Classes  ?

  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 35/00 - Antineoplastic agents

5.

RXRα BINDERS AND RXRα/PLK1 MODULATORS

      
Application Number CN2020134263
Publication Number 2022/120523
Status In Force
Filing Date 2020-12-07
Publication Date 2022-06-16
Owner NUCMITO PHARMACEUTICALS CO. LTD. (China)
Inventor
  • Zhang, Xiaokun
  • Xie, Guobin
  • Zhou, Yuqi
  • Su, Ying

Abstract

Provided herein are retinoid X receptor alpha binders that specifically bind to an epitope of a retinoid X receptor alpha, wherein the epitope comprises a phosphorylated serine at position 56 or 70. Also provided herein are retinoid X receptor alpha/polo-like kinase 1 modulators that inhibit the interaction of a polo-like kinase 1 with a retinoid X receptor alpha comprising a phosphorylated serine at position 56 or 70.

IPC Classes  ?

  • A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • A61P 35/00 - Antineoplastic agents

6.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Application Number CN2021099626
Publication Number 2021/249529
Status In Force
Filing Date 2021-06-11
Publication Date 2021-12-16
Owner NUCMITO PHARMACEUTICALS CO., LTD. (China)
Inventor
  • Su, Ying
  • Zhang, Xiaokun
  • Chen, Ziwen
  • Chen, Qiangzhen
  • Wang, Haishan
  • Zhang, Xindao
  • Zeng, Zhiping
  • Cai, Lijun
  • Zhou, Yuqi

Abstract

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

IPC Classes  ?

  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes
  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61P 35/00 - Antineoplastic agents

7.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Document Number 03182036
Status Pending
Filing Date 2021-06-11
Owner NUCMITO PHARMACEUTICALS CO., LTD. (China)
Inventor
  • Su, Ying
  • Zhang, Xiaokun
  • Chen, Ziwen
  • Chen, Qingzhen
  • Wang, Haishan
  • Zhang, Xindao
  • Zeng, Zhiping
  • Zhou, Yuqi
  • Yan, Zhiqiang

Abstract

Provided herein are an indene compound, e.g., a compound of Formula (I), and a pharmaceutical composition thereof. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.

IPC Classes  ?

  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes

8.

INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

      
Document Number 03273625
Status Pending
Filing Date 2023-11-15
Owner NUCMITO PHARMACEUTICALS CO. LTD. (China)
Inventor
  • Chen, Ziwen
  • Su, Ying
  • Wang, Haishan

IPC Classes  ?

  • A61K 31/015 - Hydrocarbons carbocyclic
  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • C07C 13/465 - IndenesCompletely or partially hydrogenated indenes